TrialDiagnostic pathology2016

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.

Marlon C Rebelatto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.